These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
208 related articles for article (PubMed ID: 27916821)
21. [TP53 mutations and molecular epidemiology]. Otsuka K; Ishioka C Gan To Kagaku Ryoho; 2007 May; 34(5):683-9. PubMed ID: 17496437 [TBL] [Abstract][Full Text] [Related]
22. Regulation of p53 by ING family members in suppression of tumor initiation and progression. Jafarnejad SM; Li G Cancer Metastasis Rev; 2012 Jun; 31(1-2):55-73. PubMed ID: 22095030 [TBL] [Abstract][Full Text] [Related]
23. A mechanistic study of the proapoptotic effect of tolfenamic acid: involvement of NF-κB activation. Jeong JB; Yang X; Clark R; Choi J; Baek SJ; Lee SH Carcinogenesis; 2013 Oct; 34(10):2350-60. PubMed ID: 23784084 [TBL] [Abstract][Full Text] [Related]
24. Functional interactions between p53 and the TFIIH complex are affected by tumour-associated mutations. Léveillard T; Andera L; Bissonnette N; Schaeffer L; Bracco L; Egly JM; Wasylyk B EMBO J; 1996 Apr; 15(7):1615-24. PubMed ID: 8612585 [TBL] [Abstract][Full Text] [Related]
31. Transcription-independent p53 apoptosis: an alternative route to death. Speidel D Trends Cell Biol; 2010 Jan; 20(1):14-24. PubMed ID: 19879762 [TBL] [Abstract][Full Text] [Related]
32. Cell death decision by p53 via control of the mitochondrial membrane. Dashzeveg N; Yoshida K Cancer Lett; 2015 Oct; 367(2):108-12. PubMed ID: 26231733 [TBL] [Abstract][Full Text] [Related]
33. Mutant p53 reactivation by small molecules makes its way to the clinic. Bykov VJ; Wiman KG FEBS Lett; 2014 Aug; 588(16):2622-7. PubMed ID: 24768524 [TBL] [Abstract][Full Text] [Related]
34. p53 dysfunction precedes the activation of nuclear factor-κB during disease progression in mice expressing Tax, a human T-cell leukemia virus type 1 oncoprotein. Ohsugi T; Ishida T; Shimasaki T; Okada S; Umezawa K Carcinogenesis; 2013 Sep; 34(9):2129-36. PubMed ID: 23633516 [TBL] [Abstract][Full Text] [Related]
35. Role of T antigen interactions with p53 in tumorigenesis. Pipas JM; Levine AJ Semin Cancer Biol; 2001 Feb; 11(1):23-30. PubMed ID: 11243896 [TBL] [Abstract][Full Text] [Related]
36. Different mutation profiles associated to P53 accumulation in colorectal cancer. López I; P Oliveira L; Tucci P; Alvarez-Valín F; A Coudry R; Marín M Gene; 2012 May; 499(1):81-7. PubMed ID: 22373952 [TBL] [Abstract][Full Text] [Related]
37. Induction of genetic instability by gain-of-function p53 cancer mutants. Xu Y Oncogene; 2008 Jun; 27(25):3501-7. PubMed ID: 18223686 [TBL] [Abstract][Full Text] [Related]
38. Discriminating functional and non-functional p53 in human tumours by p53 and MDM2 immunohistochemistry. Nenutil R; Smardova J; Pavlova S; Hanzelkova Z; Muller P; Fabian P; Hrstka R; Janotova P; Radina M; Lane DP; Coates PJ; Vojtesek B J Pathol; 2005 Nov; 207(3):251-9. PubMed ID: 16161005 [TBL] [Abstract][Full Text] [Related]
39. CHK1 regulates NF-κB signaling upon DNA damage in p53- deficient cells and associated tumor-derived microvesicles. Carroll BL; Pulkoski-Gross MJ; Hannun YA; Obeid LM Oncotarget; 2016 Apr; 7(14):18159-70. PubMed ID: 26921248 [TBL] [Abstract][Full Text] [Related]
40. Pharmacologic activation of wild-type p53 by nutlin therapy in childhood cancer. Van Maerken T; Rihani A; Van Goethem A; De Paepe A; Speleman F; Vandesompele J Cancer Lett; 2014 Mar; 344(2):157-65. PubMed ID: 24262662 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]